Glaukos Corporation
26061 Merit Circle
Suite 101
Laguna Hills
California
92653
United States
Tel: 949-367-9600
222 articles about Glaukos Corporation
-
Glaukos Corporation Announces Fourth Quarter and Full Year 2020 Financial Results
2/25/2021
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2020.
-
Glaukos Announces Positive Phase 3 Trial Results for iLink™ Epi-on Investigational Therapy That Met the Primary Efficacy Endpoint
2/25/2021
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that U.S. Phase 3 pivotal trial results for its next-generation corneal cross-linking iLink™ therapy for the treatment of keratoconus, known as Epi-on,
-
Glaukos Corporation to Release Fourth Quarter and Full Year 2020 Financial Results after Market Close on February 25
2/4/2021
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2020 financial results after the market close on Thursday, February 25, 2021.
-
Orsini Specialty Pharmacy Selected By Glaukos® Corporation As A Specialty Pharmacy Distribution Partner For Photrexa® And Photrexa® Viscous
1/19/2021
Orsini Specialty Pharmacy, a leader in rare diseases and gene therapies, announced that it has been selected by Glaukos® Corporation as a specialty pharmacy distribution partner for Photrexa® and Photrexa® Viscous for the treatment of patients with progressive keratoconus and corneal ectasia following refractive surgery See Full Prescribing Information.
-
U.S. IDE Trial Results for Glaukos’ iStent infinite™ Show Substantial Reduction in IOP
1/13/2021
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that 12-month U.S. Investigational Device Exemption (IDE) pivotal trial data showed that its iStent infinite™ Trabecular Micro-Bypass System
-
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2020 Net Sales
1/13/2021
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2020.
-
Glaukos Announces Participation in J.P. Morgan Healthcare Conference - Dec 23, 2020
12/23/2020
Glaukos Corporation announced that its management is scheduled to virtually participate in the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021, at 11:00 a.m. PST.
-
Glaukos Announces Participation in Upcoming Investor Conferences - Nov 11, 2020
11/11/2020
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced that its management is scheduled to virtually participate in the following upcoming investor conferences:
-
Glaukos Corporation Announces Third Quarter 2020 Financial Results
11/5/2020
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced financial results for the third quarter ended September 30, 2020.
-
Glaukos Corporation to Release Third Quarter 2020 Financial Results after Market Close on November 5
10/15/2020
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quarter 2020 financial results after the market close on Thursday, November 5, 2020. The company’s management will discuss the results during
-
Glaukos Announces Participation in September 2020 Investor Conferences
9/4/2020
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced that its management is scheduled to virtually participate in the following upcoming investor conferences
-
Glaukos Corporation Announces Second Quarter 2020 Financial Results
8/6/2020
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2020.
-
Glaukos Corporation to Release Second Quarter 2020 Financial Results after Market Close on August 6
7/20/2020
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2020 financial results after the market close on Thursday, August 6, 2020.
-
Glaukos Corporation Announces Pricing of Private Offering of $250 Million of 2.75% Convertible Senior Notes - June 09, 2020
6/9/2020
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced the pricing of its private offering of $250 million aggregate principal amount of 2.75% Convertible Senior Notes due 2027.
-
Glaukos Announces Presentation Cancellation at the William Blair 40th Annual Growth Stock Conference
6/9/2020
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that in light of the company’s offering of its 2.75% Convertible Senior Notes due 2027
-
Glaukos Corporation Announces Proposed Private Offering of $200 Million of Convertible Senior Notes
6/8/2020
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced that it intends to offer, subject to market and other conditions, $200 million aggregate principal amount of Convertible Senior Notes due 2027 in a private offering.
-
Glaukos Announces Participation in the William Blair 40th Annual Growth Stock Conference
6/2/2020
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the William Blair 40th Annual Growth Stock Conference on Wednesday, June 10, 2020, at 3:20 p.m. CDT.
-
Glaukos Technologies Featured in Numerous Presentations at the 2020 American Society of Cataract and Refractive Surgery Virtual Annual Meeting
5/15/2020
Dr. Samuelson to Present First-of-its-Kind MIGS Prospective Study Demonstrating Statistical Improvements in Vision-Related Quality of Life from a Pivotal Trial SAN CLEMENTE, Calif.--( BUSINESS WIRE )-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in var
-
Glaukos Corporation Announces First Quarter 2020 Financial Results
5/7/2020
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced financial results for the first quarter ended March 31, 2020.
-
Glaukos Corporation to Release First Quarter 2020 Financial Results after Market Close on May 7
4/21/2020
Conference Call and Webcast Scheduled for 1:30 p.m. PDT